Should I buy EBOS Group stock in 2025?

What is the EBOS Group?

How much is the EBOS Group stock?

The price of EBOS Group stock is declining this week. As of now, the current share price stands at AU$34.40, reflecting a small drop of AU$0.02 (-0.06%) over the past 24 hours and a weekly decrease of 3.23%.

EBOS Group holds a market capitalisation of AU$7.02 billion, with an average three-month trading volume of 70,010 shares. The stock trades at a P/E ratio of 27.04, offers a dividend yield of 3.26%, and reports a low beta of 0.42, indicating comparatively stable performance.

This lower volatility profile may appeal to NZ investors seeking steady exposure within the defensive healthcare sector.

Our complete analysis of the EBOS Group stock

After a thorough review of EBOS Group’s most recent financial results and stock performance over the past three years, coupled with proprietary algorithms blending financial metrics, technical signals, market dynamics, and peer group analysis, we believe the stock merits increased investor attention. The group’s resilience in healthcare distribution and its ongoing strategic moves set the stage for a compelling valuation narrative. So, why might EBOS Group stock once again become a strategic entry point into the Australasian and Asia-Pacific healthcare sector in 2025?

Recent Performance and Market Context

EBOS Group (ASX: EBO) continues to demonstrate robust underlying business momentum, particularly notable amid sector and contract upheavals. As of 30 May 2025, EBOS traded at AU$34.40, delivering a one-year gain of +10.47% even as it saw a mild six-month contraction (-2.13%) and slight weekly dip (-3.23%). This recent softness appears less a sign of structural weakness, and more a typical consolidation phase following strong outperformance.

Positive developments underpin the fundamental story:

• Strong H1 FY2025 results: Despite the loss of a major contract (Chemist Warehouse Australia), EBOS delivered solid organic growth, exceeding market expectations.
• Successful capital raising in April–May 2025 brought in AU$254 million, enhancing financial flexibility for strategic expansion.
• Expansion in Southeast Asia with targeted acquisitions (~AU$70 million), deepening EBOS’ exposure to fast-growing healthcare technology and distribution channels.

The broader macroeconomic backdrop is constructive. Healthcare distribution remains a defensive sector, offering protection against broader market volatility and benefiting from demographic tailwinds across both Australia and New Zealand. Furthermore, the increasing regional demand for sophisticated health solutions, driven by population growth and urbanisation in Asia-Pacific, creates a favourable backdrop for EBOS’ long-term growth ambitions.

Technical Analysis

Technically, EBOS presently offers an intriguing set-up for prospective investors seeking strategic entry points. The 14-day RSI stands at 40.25, reflecting a neutral stance—crucially, it avoids “overbought” territory and hints at renewed upward momentum potential. The MACD (+0.16) has shifted to a bullish signal, marking the beginning of positive price inflection.

Though short-term moving averages (20/50/100-day) currently indicate mild downside pressure (all above the present price, signifying recent correction), the 200-day moving average (AU$33.82) sits below the last close, providing a solid support base and flagging possible long-term trend re-engagement. Notably, the key support level at AU$34.78 (S3) has shown resilience, while resistance at AU$36.70 presents a near-term technical target. EBOS also trades comfortably within its 52-week range (AU$28.75–AU$38.09), suggesting room for further appreciation.

Here’s why investors may view the current market structure as promising:

• Favourable MACD crossover
• Neutral RSI exposes minimal overheating risk
• Strong support near 200-day moving average
• Potential for bullish reversal should the AU$36–37 zone be breached on volume

This convergence of signals suggests that EBOS may be poised to shift from consolidation back into a medium-term uptrend—an attractive scenario for buyers seeking value.

Fundamental Analysis

Fundamentally, EBOS stands out as a defensive growth leader in the Australasian healthcare supply chain, boasting both scale and agility. The company’s H1 FY2025 performance shone, with:

That growth is particularly impressive given the broader sector headwinds, underscoring EBOS’ capacity for agile portfolio management and its solid cost discipline.

Further supporting the valuation case:

• Attractive dividend yield (3.26%), well above market peers in defensive sectors, reflecting stable cashflows and a reliable return component.
• Consensus price target at AU$40.25, implying a further 7.91% potential upside from current levels.
• P/E ratio of 27.04 appears justified given the robust projected EBITDA (AU$575–600 million for FY2025) and defensive sector premium.

Competitive advantages fortify the bull case:

• Sector leadership: #1 distributor for pharmaceuticals and animal care in Australasia
• Geographic diversification: Deepening roots in Southeast Asia mitigate local contract volatility
• Structural tailwinds: Growing demand for healthcare (ageing population, pet care, pharma distribution)
• Track record of innovation: Strategic investments, especially in digital health and medical technology distribution

EBOS’ business model, combining pharmaceuticals, medical devices, and animal care, builds a high-quality earnings base less susceptible to sector-specific shocks. Management’s focus on operational and capital efficiency—evident in ambitious cost-reduction goals (~AU$25–50 million savings by FY26)—positions the group for margin expansion.

Volume and Liquidity

Market confidence remains strong, reflected in an average daily volume of 70,010 shares and a healthy public float (151.86 million shares out of 203.23 million outstanding). This liquidity ensures efficient price discovery and facilitates meaningful portfolio allocations for both institutional and retail investors in NZ and Australia.

Key attributes supporting dynamic valuation include:

• Robust average volumes maintain price stability, even through periods of heightened volatility
• Float structure permits broad market access and supports orderly capital inflows without excessive price disruption

As a result, EBOS shares remain accessible to investors seeking both growth and income, with volume patterns underscoring persistent institutional participation.

Catalysts and Positive Outlook

Several catalysts point to structural upside in the medium to long term:

• New distribution contracts worth AU$450 million annually will provide incremental revenue streams.
• Strategic expansion in Southeast Asia: Acquisitions in Malaysia and the Philippines target high-growth healthcare technology segments, unlocking scalability.
• Animal Care momentum: Premium brands (Black Hawk, Vitapet) position EBOS to leverage rising pet care demand, a secular growth theme with resilient margins.
• Cost-saving initiatives (AU$25–50 million target by FY26) will drive operating leverage, augmenting cash generation.
• ESG and sustainability focus: Enhanced transparency, regional leadership in product stewardship, and responsible supply chain management make EBOS increasingly attractive to institutional stakeholders.

Market sentiment remains robust, as evidenced by the consensus “OUTPERFORM” rating from leading brokers. Analysts remain positive on the company’s ability to replace lost revenue, maintain double-digit growth ex-contract, and extract further value via acquisitions and cost optimisation.

The combination of these structural and tactical drivers suggests EBOS is on track to consolidate and extend its leadership across Australasia and into new Asian markets—a scenario well-supported by demographic, regulatory, and technological change.

Investment Strategies

For investors evaluating an entry into EBOS Group, the current juncture presents distinct advantages across different horizons:

Short-term positioning:

• Recent technical support at AU$34.78 and convergence of short-term oversold indicators flag a potentially attractive tactical buy point.
• Advancement past the AU$36.70 resistance could trigger upside momentum.

Medium-term approach:

• As cost synergies from recent acquisitions are realised and new contracts begin contributing, operational momentum should drive earnings upgrades over 6–12 months.
• Portfolio managers targeting reliable yield and defensiveness in volatile equity markets may find the 3.26% dividend yield and low beta (0.42) appealing.

Long-term thesis:

• Investors looking to tap into secular healthcare and pet care growth, regional M&A opportunities, and a balanced, scalable business model may see strong compounding potential.
• Geographic diversification and recurring revenues from defensive end-markets (healthcare/animal care) reduce risk and enhance earnings visibility.
• Buying during periods of technical consolidation—especially around major supports or ahead of key catalysts (full-year results, contract wins)—can be particularly opportune.

In sum, ideal positioning appears to converge on current pricing, with the possibility of scaling in further should technical confirmation or fundamental catalysts (earnings announcements, new contract disclosures) materialise in the coming quarters.

Is it the Right Time to Buy EBOS Group?

The strategic argument for EBOS Group is compelling: the company stands out for its deep sectoral moats, defensive growth profile, and capacity to drive earnings growth even during transitional periods. With a proven management team, sector-leading dividend yield, clear medium-term catalysts, and a positive analyst backdrop, the fundamentals justify renewed investor interest.

• Key strengths: Highly defensive sector, proven resilience to contract volatility, attractive yield, ongoing regional expansion, steady cost discipline, and a consensus bias for outperformance.
• Outlook: The technical consolidation appears to be stabilising near key supports, hinting at reacceleration; fundamental value drivers (EBITDA growth, new contracts, M&A) are only just being priced in.

While past performance is never a guarantee of future returns, the sum of technical, fundamental, and strategic indicators suggests that EBOS Group seems to represent an excellent opportunity for investors seeking exposure to high-quality Australasian healthcare and animal care markets with long-term compounding potential.

Viewed in this light, EBOS Group may be entering a new bullish phase—one intensifying as cost savings and new revenue streams flow through. The convergence of strong fundamentals, attractive valuation, and multiple growth catalysts warrant serious consideration for any investor evaluating robust, future-ready healthcare exposure in the Australasian or Asia-Pacific context.

For those seeking a combination of yield, growth, and sectoral resilience, EBOS Group stands poised as one of the most promising names in the region—offering not just defensive strength, but a platform for outperformance as health innovation and regional dynamism gather pace.

How to buy EBOS Group stock in New Zealand?

Buying EBOS Group shares online is easier and safer than ever before for New Zealand investors. By using a regulated online broker, you can quickly place an order to purchase EBOS Group (ASX:EBO) stock, benefiting from modern digital platforms designed with security and investor protection in mind. There are two main methods to choose from: traditional spot (cash) buying, where you own the shares directly, or trading Contracts for Difference (CFDs), which allow you to speculate on price movements with the option of leverage. Below, you’ll find a comparison to help you select the broker and approach that best suit your needs.

Spot (Cash) Buying

With cash buying, you purchase EBOS Group shares outright on the Australian Securities Exchange (ASX), giving you direct ownership. You may be eligible to receive dividends and benefit from any long-term appreciation in the share price. Most reputable NZ brokers charge a fixed commission per order—this is typically around NZ$5–$12, depending on the platform.

Practical example

Suppose EBOS Group is trading at AU$34.40 per share, and you invest NZ$1,000. Allowing for a brokerage fee of about NZ$5 and factoring in a typical exchange rate close to parity, you could buy approximately 29 shares ($1,000 ÷ $34.40 ≈ 29), after fees.

✔️ Gain scenario

If the share price rises by 10%, your 29 shares would now be worth NZ$1,100.
Result: +NZ$100 gross gain, or +10% on your investment, not including any dividends.

Trading EBOS Group via CFDs

CFDs (Contracts for Difference) let you trade EBOS Group shares without actually owning them. Instead, you speculate on the price movements—either up or down. CFDs are offered by regulated brokers and allow for leverage, typically up to 5x for blue-chip shares.

CFD trading fees usually involve a spread (the difference between the buying and selling price), plus overnight financing costs if you hold leveraged positions for more than a day. It’s important to understand these charges may reduce your net gains.

Practical example

With NZ$1,000, you open a CFD position on EBOS Group with 5x leverage, giving you market exposure of NZ$5,000.

✔️ Gain scenario

If EBOS Group’s price rises by 8%, your position gains 8% × 5 = 40%. That means a NZ$400 gain (excluding fees and charges) on your NZ$1,000 outlay.

Final Advice

Before investing, it is essential to compare broker fees, trading conditions, and available features. Take time to review the full broker comparison further down this page to find the option best suited to your investment goals and style. Whether you choose direct ownership (spot buying) for long-term investing or CFDs for active, short-term trading, your decision should match your risk tolerance, return expectations, and financial objectives.

Our 7 tips for buying EBOS Group stock

The latest news about EBOS Group

EBOS Group has reaffirmed robust growth and maintained FY25 EBITDA guidance despite recent market headwinds. Following the release of its H1 FY2025 results at the end of May, EBOS Group highlighted resilient organic growth of 7.1% (excluding the impact of the Chemist Warehouse Australia contract loss) and a net profit of AU$131 million, beating market expectations. The reaffirmed guidance, with FY25 EBITDA targeted between AU$575 and AU$600 million, signals continued confidence in its core operations in Australia and New Zealand and supports investor sentiment regarding the stability of its healthcare distribution business in the region.

A successful AU$254 million capital raise expands capacity for strategic investments and strengthens the balance sheet. During April and May 2025, EBOS completed a placement and retail offer raising AU$254 million, directly enhancing its ability to pursue growth initiatives and solidifying its financial flexibility. This fresh capital is particularly relevant to the New Zealand investor base, ensuring the group remains well-positioned to support ongoing expansion and mitigate the impact of recent changes in major client contracts, thereby maintaining its competitive edge in the trans-Tasman healthcare supply market.

Strategic acquisitions in Southeast Asia accelerate diversification and add new revenue streams without compromising regional leadership. Recently, EBOS Group finalized three acquisitions in Malaysia and the Philippines, focusing on medtech and orthopaedics for approximately AU$70 million. These targeted expansions reinforce the company’s plans to diversify beyond the ANZ region while sustaining its role as the leading pharmaceutical distributor for New Zealand and Australia. The increased scale and cross-border expertise are expected to contribute positively to group results and de-risk future revenue streams for local shareholders.

New pharmaceutical distribution contracts valued at over AU$450 million annually support organic growth and improve revenue visibility. The addition of significant new contracts, announced in May 2025, provides a strong uplift to forecasted revenues and underlines continued trust from major healthcare providers. This improves the company’s medium-term outlook in both Australia and New Zealand, directly benefiting NZ investors. Combined with ongoing cost-saving initiatives targeting AU$25–50 million through to FY26, these contracts mitigate past contract losses and enhance the group’s competitive positioning.

Analyst sentiment remains positive, with consensus rating EBOS as “OUTPERFORM” and forecasting potential price upside. Despite the stock’s recent short-term underperformance (down 3.2% over the past week), analysts maintain a consensus price target of AU$40.25, representing a potential upside of nearly 8% from current levels. EBOS offers a defensive profile in the healthcare sector, reliable dividends (current yield at 3.26%), and low volatility (beta of 0.42), making it an attractive option for New Zealand investors seeking stable, long-term equity returns within the region’s essential services sector.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.